(TheNewswire)
October 4th, 2018 / TheNewswire
/ Vancouver, British Columbia - BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B)
(OTCMKTS: BMKDF) is pleased to announce that further to its press release of September 20, 2017, it has closed the
final tranche of a non-brokered private placement for gross proceeds of $222,100.00 wherein BioMark issued 2,221,000 units at a
price of $ 0.10 per unit.
Each unit consists of one common share of BioMark and one-half of one share purchase warrant. One whole share
purchase warrant will entitle the holder thereof to purchase one common share of BioMark at $0.15 per share for a period of two
years from the closing date of the private placement, subject to an acceleration clause. No Finders’ fees were payable on the
private placement.
The proceeds of the private placement will be used for the continuation of the Company's regulatory submission
costs, patent costs, sample acquisition costs and general working capital. The securities issued under the private placement will
be subject to a hold period of four months and one day.
Certain Insiders, Directors and Officers subscribed for a portion of this placement. Participation of the
insiders of the Company in the private placement constitutes a related party transaction as defined under Multilateral Instrument
61-101 (Protection of Minority Security Holders in Special Transactions). Because
the Company’s shares trade only on the CSE, the issuance of securities is exempt from the formal valuation requirements of Section
5.4 of MI 61-101 pursuant to Subsection 5.5(b) of MI 61-101 and exempt from the minority approval requirements of Section 5.6 of MI
61-101. The Company did not file a material change report 21 day prior to the closing of the private placement as the details of
the participation of insiders of the Company had not been confirmed at that time.
About BioMark Diagnostics Inc.
BioMark Diagnostics is developing proprietary, non-invasive, and accurate cancer diagnostic solutions, which
can help detect, monitor and assess treatment for cancer early and cost effectively. The technology can also be used for measuring
response to treatment and potentially for serial monitoring for cancer survivors. For more information please visit
the company website at: www.biomarkdiagnostics.com
On Behalf of the Board of Directors
BIOMARK DIAGNOSTICS INC.
“Rashid Ahmed Bux”
CEO and Director
Contact Information
Rashid Ahmed Bux – President & CEO
BioMark Diagnostics Inc.
Tel. 604-370-0779
Email: info@biomarkdiagnostics.com
Forward-Looking Information:
This press release may include forward-looking information within the meaning of Canadian securities
legislation, concerning the business of BioMark. Forward-looking information is based on certain key expectations and
assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on
which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking
information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this
press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any
forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required
by applicable securities laws.
This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities
described herein in the United States. The securities described herein have not been and will not be registered under the United
States Securities Act of 1933, as amended, or any applicable securities laws or any state of the United States and may not be
offered or sold in the United States or to the account or benefit of a person in the United States absent an exemption from the
registration requirements.
The CSE has not reviewed, approved or disapproved the content of this press release.
Copyright (c) 2018 TheNewswire - All rights reserved.